Conferences

 

 

1st INTERNATIONAL CONFERENCE ON NANODRUGS AND

CLINICAL NANOTECHNOLOGY

Date: 23rd-24th October 2008

! Now co-located with Regenerative Therapies 2008 Conference

Venue and Location: The Grosvenor, Buckingham Palace Road, London, UK

OVERVIEW......................................................................................................................

Nanotechnology has the potential to revolutionize medical treatments and medical practice. With hundreds of nanodrugs in development globally, the opportunities for clinical and market successes are apparent. Nanodrugs are at the forefront of bioengineering for diseases such as cancer, cardiovascular disease, and age-related conditions and represent the next generation of medical therapies that will impact worldwide markets, healthcare, and industry.

Arrowhead-Spectra's 1st International Conference on NanoDrugs and Clinical NanoTechnology provides an unmissable forum to learn the challenges and advances of pioneers in nanodrug development and be updated on the nanotechnologies applied to medical therapies. Case studies of pipelines, progress and clinical efficacy, and challenges of bioengineering and manufacturing will be the main themes of the conference.

The two-day expert-led event includes an Intellectual Property Workshop, a Masterclass, and presentations from leading international companies and institutes researching and developing nanomedicines.

INTELLECTUAL PROPERTY WORKSHOP: Organised by Foley & Lardner LLP, USA ..... Workshop Leader: Mr Stephen Maebius, Partner

International law firm, Foley & Lardner LLP, invite delegates to join them for an interactive workshop featuring three leading practitioners from the US, Europe and Japan to discuss global patent strategy in the nanomedicine field. The workshop will include comparative case studies of successful strategies employed on a global basis to obtain maximum patent protection in the key jurisdictions.

Additional areas to be covered in the workshop are as follows:

  • Protecting combination products that incorporate nanomaterials for targeted drug delivery;
  • Strategies for broadly claiming small particle formulations;
  • Understanding how much data is needed to support broad nanomedicine claims in the key jurisdictions of the US, Europe and Japan;
  • Major global trends impacting the scope of protection in nanomedicine inventions.

PRESENTATION TOPICS INCLUDING:

  • Nanoparticle-Mediated Systemic Tumour Suppressor Gene Delivery for Lung Cancer: Moving Beyond the Laboratory;
  • FDA considerations for the regulation of nanomaterial-containing products: a perspective from the CDER;
  • Dendrimers in Pharmaceutical Applications;
  • Nanomedicines for the Enhancement of Drug Bioavailability;
  • The Competitive Landscape of Nanotechnology in Drug Delivery;
  • Polyelectrolytes in Medicine: Multifunctional Nanotools;
  • Capital Funding Issues for Nanomedicines;
  • Nanodrug Clinical Case Studies;
  • Manufacturing and Scalability Issues for Nanomedicines;
  • Overcoming Big Challenges in Making Small Products to Make Big Differences in Drug Targeting;
  • Beyond Nano-Publicity - A Realistic Business Case for Pharma;
  • RNAi NanoplexTM Technology for Systemic Delivery of siRNA Therapeutics for the Treatment of Cancer;
  • Nanofunctional Interfaces for Nanoscale Biomedical Imaging.

Click here to Request Brochure

WHY ATTEND?................................................................................................................................... ...........

  • Learn the latest developments in nanodrug development and clinical nanotechnology;
  • Better understand the trends of nanodrug development;
  • Learn from experts on the challenges and the solutions to bioengineering and manufacturing;
  • Determine the efficacy of clinical stage nanodrug products;
  • Establish the next generation market leaders in cancer and other therapy areas;
  • Network with leaders from nanotechnology, pharma-biotech and healthcare industries

Who Should Attend

Individuals from nanotechnology, biotechnology, pharmaceutical, and capital investment companies will greatly benefit from attending. Also researchers and scientists in academia will also find the event useful and informative.

Executive and professional job types may include:

  • Senior executive management: CEO, VP, CSO
  • Research and development executives
  • Academic research scientists
  • Medical scientists
  • Healthcare media organizations
  • Medical and healthcare journalists
  • Venture capitalists

UNABLE TO ATTEND?

If you are unable to attend the conference on the day we are streaming a Live WebCast so that you can access the expert presentations realtime in office or home environments. Webinars of the conference will also be available after the event. The WebCast will be suitable for UK/EU delegates but because of time zone differences, North American and Rest of World delegates may wish to opt for the webinar.

PRICING

10% Early Bird Discounts for registrations before 1st August 2008!..................... (Discounted price shown on RegOnline, but full price shown below):

Full Delegate (attendance at both days): £1,100 | US$2,100

Full Delegate plus Executive Workshop: £1,350 | US$2,600

Day-only Delegate (attendance at either day): £750 | US$1,400

Academic and Non-Commercial Delegate: £650 | US$1,200

Executive Workshop only: £250 | US$495

*Live WebCast Delegate 2-day (UK/EU): £799 | US$1,500

*Live WebCast Delegate 1-day (UK/EU): £499 | US$900 [*North American delegates may wish to receive the Live WebCast but time zone differences may prohibit full access. Please contact us if you wish to access the afternoon session.]

Webinar (Conference archive delivered online after event): £750 | US$1,400

Promotional Literature Distribution: £850 | US$1600 [**Distribution of your company's promotional literature to all full conference delegates]

NB. Prices quoted above in US$ are approximations and currency variations and exchange rates will vary on a daily basis relative to the GB£ price.

VENUE

The Grosvenor at Victoria............................................................................................... 101 Buckingham Palace Road, London SW1W OSJ

For Directions and Hotel Overview click here

HOTEL ACCOMMODATION

Call The Grosvenor reservations direct on +44 (0)20 7868 6248 and quote code 'SPEC100908' to receive special rates on Standard or Executive Suites.

Please use the ebookers.com links below to find flight information and alternative central London hotels.

ebookers hotel offers ebookers flights

 

SPONSORSHIP AND MEDIA OPPORTUNITIES

To enquire about sponsorship and/or exhibiting at this conference please contact marketing@arrowheadpublishers.com

CONTACT US

For more infomation about this conference, please contact us at +44(0) 208 671 7726 or email us at conferences@spectraintelligence.com

CANCELLATIONS AND REFUNDS

Conferences Cancellation Policy:

Cancellations received in writing up to 4 weeks before the conference date will be issued a full credit voucher to be applied to another Spectra event within 12 months. Cancellations received in writing later than 4 weeks before the conference date will receive a credit voucher, less a £200 administration fee, to be applied to another Spectra event within 12 months. Delegate substitution is permitted for both registration and credit vouchers. Please contact us at registrations@spectraintelligence.com for further information.

 

 

NANODRUGS 2008

SPEAKER PANEL INCLUDES:

Professor Ijeoma Uchegbu Department of Pharmaceutics.............. School of Pharmacy, ................................ University of London, UK

Dr Silke Krol .......................... Senior Scientist & Head of the NanoBioMed Group Laboratory for Nano-diagnostics, Drug Delivery and Analysis, Center of Molecular Biomedicine (CBM), Italy

Dr Thomas Keller................... Director - Biophysical Sensors & Nanomaterials, GlaxoSmithKline...... Research & Development, UK

Professor Rajagopal Ramesh Department of Thoracic and Cardiovascular Surgery, M.D.Anderson Cancer Center, USA

 

Mr Mark Bünger..................... Research Director Lux Research, USA

 

Dr Xiaodong Yang.................. Vice President, Research and Preclinical Development, Intradigm Corp., USA

 

Dr Nakissa Sadrieh......... Associate Director for Research Policy and Implementation, Center for Drug Evaluation and Research, Food and Drug Administration, USA

Mr Stephen Maebius........ Partner, Foley & Lardner LLP, US

 

Dr Christof Fattinger............ Head of Microtechnologies and Automation, Discovery Technologies,.F. Hoffmann-La Roche, Switzerland

 

Dr Julianna Lisziewicz... President and Chief Executive Officer, Genetic Immunity, Hungary

 

...Plus many others confirmed

 

 


View our Privacy Policy here

 

home | about us | research & analysis | spectra reports | conferences | contact us